Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 4/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5496367 | 0.84 | CCR2 (0.53) | CCR2PTGER3ARSMN1; SMN2TP53 | |
| SCHEMBL5493355 | 0.81 | CCR2 (0.63) | CCR2PTGER3MAOBSMN1; SMN2MAPT | |
| SCHEMBL5489790 | 0.81 | CCR2 (0.64) | CCR2PTGER3MAOBSMN1; SMN2MAPT | |
| SCHEMBL5491143 | 0.79 | MAOB (0.56) | CCR2PTGER3MAOBSMN1; SMN2TP53 | |
| SCHEMBL6179586 | 0.76 | PTGER3 (0.49) | CCR2PTGER3SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL14364237 | 0.74 | CCR2 (0.64) | CCR2PTGER3MAOBSMN1; SMN2MAPT | |
| SCHEMBL8773512 | 0.74 | PTGER3 (0.56) | PTGER3MAOBSMN1; SMN2TP53MAPT | |
| SCHEMBL6125954 | 0.74 | PTGER3 (0.56) | PTGER3MAOBSMN1; SMN2TP53MAPT | |
| SCHEMBL5778627 | 0.73 | CCR2 (0.53) | CCR2CCR5ARMAOBSMN1; SMN2 | |
| SCHEMBL5780051 | 0.73 | CCR2 (0.53) | CCR2CCR5ARMAOBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363897-B1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK INC (US) | 2005-12-21 | — | — | EP | claimed |
| US-20050054668-A1 | Antagonists of MCP-1 function and methods of use thereof | LABORDE EDGARDO (US) | 2005-03-10 | — | — | US | claimed |
| US-20030105085-A1 | Antagonists of MCP-1 function and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2003-06-05 | — | — | US | claimed |
| US-6809113-B2 | FOR THERAPY OF ARTHRITIS, ASTHMA, ATHEROSCLEROSIS, DIABETIC NEPHROPATHY, INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE, MULTIPLE SCLEROSIS, NEPHRITIS, PANCREATITIS, PULMONARY FIBROSIS, PSORIASIS, RESTENOSIS TRANSPLANT REJECTION | TELIK, INC. | 2004-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105085-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | CCR2 1/4885CCR5 5/4885PTGER3 496/4885 |
| US-20050054668-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | CCR2 1/4885CCR5 5/4885PTGER3 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.